StockData

Biofrontera vs Pelthos Therapeutics

BFRI and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BFRI and PTHS compare

Pelthos Therapeutics is the larger company, worth 3.2 times as much as Biofrontera ($27.4M against $8.5M).

Biofrontera keeps more of each dollar of sales as profit, with a net margin of −13.8% compared with −200% at Pelthos Therapeutics.

Biofrontera scores higher on the StockData Score (10 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBFRIPTHS
Size and price
Market cap$8.5M$27.4M
Share price$0.570$7.15
Change, 1 year−36.0%−79.4%
Change, 5 years−99.6%–
Beta (5Y)1.960.91
Employees9292
StockData Score
Total score10 (better)2
Valuation score11
Growth score2 (better)0
Performance score2 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/S0.2× (better)0.6×
P/B1.4×–
FCF yield−93.7%–
Growth
Revenue growth (TTM)17.8%–
Revenue growth, 5Y average17.2%–
Profitability
Gross margin–78.6%
Operating margin−14.2% (better)−133%
Net margin−13.8% (better)−200%
FCF margin−17.2%–
Return on equity−988%–
Financial health
Debt / equity0.00–
Interest coverage–−7.8×
Current ratio1.181.98 (better)
Altman Z-score−6.36−1.83 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions18.6%35.6%
Held by insiders23.6%–
Insider net buying, 12 months–$794K
Short interest, % of float1.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.